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Abstract
Background: Artemether-lumefantrine (ALu) replaced sulphadoxine-pymimethamine (SP) as the official first-line
anti-malarial in Tanzania in November 2006. So far, artemisinin combination therapy (ACT) is contra-indicated
during pregnancy by the national malaria treatment guidelines, and pregnant women depend on SP for
Intermittent Preventive Treatment (IPTp) during pregnancy. SP is still being dispensed by private drug stores, but it
is unknown to which extent. If significant, it may undermine its official use for IPTp through induction of resistance.
The main study objective was to perform a baseline study of the private market for anti-malarials in Muheza town,
an area with widespread anti-malarial drug resistance, prior to the implementation of a provider training and
accreditation programme that will allow accredited drug shops to sell subsidized ALu.
Methods: All drug shops selling prescription-only anti-malarials, in Muheza town, Tanga Region voluntarily
participated from July to December 2009. Qualitative in-depth interviews were conducted with owners or
shopkeepers on saleability of anti-malarials, and structured questionnaires provided quantitative data on drugs sales
volume.
Results: All surveyed drug shops illicitly sold SP and quinine (QN), and legally amodiaquine (AQ). Calculated
monthly sale was 4,041 doses, in a town with a population of 15,000 people. Local brands of SP accounted for
74% of sales volume, compared to AQ (13%), QN (11%) and ACT (2%).
Conclusions: In community practice, the saleability of ACT was negligible. SP was best-selling, and use was not
reserved for IPTp, as stipulated in the national anti-malarial policy.
It is a major reason for concern that such drug-pressure in the community equals de facto intermittent
presumptive treatment. In an area where SP drug resistance remains high, unregulated SP dispensing to people
other than pregnant women runs the risk of eventually jeopardizing the effectiveness of the IPTp strategy.
Further studies are recommended to find out barriers for ACT utilization and preference for self-medication and to
train private drug dispensers.
Background
Anti-malarials have been widely available in private
shops for home-treatment for decades [1]. In Tanzania
drug shops known as duka la dawa baridi (DLDB),
although formally only licensed to sell over-the-counter
(OTC) drugs, frequently sell prescription-only anti-
malarials for treatment of fever or malaria, and are
important providers, often staffed by personnel with lit-
t l eo rs o m em e d i c a lt r a i n i n g ,w o r k i n gi nr u r a lm a r k e t
centres where licensed pharmacies are lacking[2]. At
present only one anti-malarial, amodiaquine (AQ), has
the status as an OTC drug, but is no longer recom-
mended; all other anti-malarials are prescription-only
drugs [3].
A national programme aims to upgrade and accredit
existing DLDBs into “accredited drug dispensing outlet”
(ADDOs) [4], to ensure that more than 80% of rural/
peri-urban areas in Tanzania mainland get opportunity
to purchase quality basic medicines from properly
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personnel after provider training. The ADDO pro-
gramme has the potential for being an important tool in
the regulation of private drugs sale, legalizing the sale of
first-line drugs, and for enforcing the national anti-
malarial drug policy in the private sector at the local
level.
Tanzania revised its drug policy in 2006, for arte-
mether-lumefantrine (ALu) to replace SP as first-line
treatment for uncomplicated malaria [5], in line with
guidelines of the World Health Organization (WHO),
which recommends artemisinin combination therapy
(ACT) in areas with resistance to previous first-line
anti-malarials [6]. With this policy, use of SP is recom-
mended only as intermittent preventive treatment dur-
ing pregnancy (IPTp). Quinine (QN) has replaced AQ
as second-line treatment, and is further indicated as
first-line treatment for children weighing less than five
kilo and their lactating mothers, and during first trime-
ster of pregnancy. Use of AQ is only indicated where no
better drug is available [5], except in Zanzibar, where
artesunate-AQ is first-line treatment.
In Tanzania mainland, ALu is provided to all govern-
mental health care facilities (subsidized by Global Fund
support), and is marketed in the media as dawa mseto;
“combination drug”.
The effects of this change in policy on the private
market for anti-malarials have been studied in districts
already covered by the ADDO programme, which so far
has been implemented only in the Morogoro, Mtwara,
Rukwa and Ruvuma Regions [7]. But little is known of
the situation in ordinary DLDBs in the market centres
elsewhere in Tanzania, and if the costly ACT may be
saleable.
A prior transition in anti-malarial drug policy in 2001,
changing the first-line treatment from chloroquine (CQ)
to SP, was initially met with negative perceptions by the
public, who feared adverse reactions reported in the
mass media, and considered the new drug and its sin-
gle-dose regimen to be too strong for them. Others
found SP to be ineffective compared to CQ, which
cleared fever more rapidly [8-12]. Thus, guidelines may
not be known nor adapted to quickly, particularly not in
private drug distribution [13,14]. Recent indications
from the study area suggest that SP may still be widely
used, as also indirectly reflected in most molecular mar-
kers of resistance remaining high (D. Ishengoma, perso-
nal communication).
The study objective was, therefore, to perform a base-
line study of the private market for anti-malarials in
Muheza town, after the malaria policy change from SP
to ALu, prior to the implementation of a provider train-
ing and accreditation programme that will allow accre-
dited drug shops to sell subsidized artemether-
lumefantrine for home-treatment. The paper describes
the sale of anti-malarials in private drug shops in
Muheza, prior to the anticipated implementation in
T a n g aR e g i o no ft h eA D D Op r o g r a m m e( s c h e d u l e dt o
2009 but delayed).
Methods
Study area
The district capital Muheza, the research site, is located
in Tanga Region at the main road connecting Mombasa,
Tanga and Dar es Salaam, with 15,000 inhabitants (in
2002) living in the three wards that comprise the district
town centre [15]. Muheza district was until recently a
high-transmission area for malaria, and with high levels
of resistance to anti-malarials, including SP [16].
Anti-malarials are within reach for most people living
in town or visiting on twice weekly market days.
Muheza is one of the 13 districts in Tanzania where the
district hospital is a designated mission hospital (Teule);
generally well supplied and well staffed, based on cost
sharing. The government health facility consists of an
old dispensary with no laboratory facilities. This serves
as the only public primary health care facility in town, it
offers free services but is mostly bypassed by patients,
who instead tend to go to the district hospital out-
patient department (OPD) where cost sharing is moder-
ate, or to one of the two private clinics or use home-
treatment with drugs bought from shops [17]. Since
2004, the number of private drug shops in Muheza
town has grown from five drug shops in 2004, to 20 in
2009, including the pharmacies of two private clinics.
Study methods
Qualitative baseline data were collected on the provider
perspectives on the saleability of the drugs presently
offered for illicit sale, and actual sale was assessed quan-
titatively, by means of in-depth open-ended interviews
and structured questionnaires respectively
Study-group and interviews
The study, conducted from July to December 2009, cov-
ered the drug shops ( d u k al ad a w ab a r i d i ;DLDB) in
Muheza town and the pharmacies of the two private
clinics that were all already selling prescription-only
anti-malarials and antibiotics, i.e. 20 private drug-outlets
in total. Weekly observations and informal in-depth
interviews in Kiswahili language, based on question
guides with shopkeepers, were the main methods
throughout the study, from July to October 2009, com-
bined with a follow-up survey in December of actual
drugs sale utilizing a structured questionnaire in
Kiswahili.
Initially consent to participate and allow observations
and interviews in shops was obtained from all twenty
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ing to be interviewed. The term shopkeeper here refers
to the person operating the shop, whether employee or
self-employed. Shopkeepers of 16 shops participated
throughout the study, including the drug sales survey,
whereas two shop-owners withdrew consent, one owner
closed one of his two shops during the study period and
another had temporarily closed down during the final
phase of the study.
The saleability of drug - their qualities that allowed
them to be sold or their perceived “value” to the consu-
mer as this was understood by the shopkeeper - was
explored by qualitative research methods i.e. ethno-
graphic interviews. This included sessions of informal
in-depth interviews and observations (seven per shop
until no new information was derived); question guides
were prepared focusing on prices and how shopkeepers
explained their customers’ preferences or ambivalences
towards the drugs they could buy in the shops. Qualita-
tive interview data consisted of verbatim notes taken in
Kiswahili while conducting the interviews. Data analysis
was exploratory, unassisted by computer software, iden-
tifying the key notions and concepts presented in the
paper.
Actual sale; the drug sales volume, was calculated
based on a survey using two structured questionnaire
interviews conducted 14 days apart, from 1
st-2 3
rd.
December 2009, after the short rainy season in Novem-
ber during which malaria transmission is somehow aver-
age for the year; in-between the dry season’sl o w
transmission and the long rainy season’sh i g ht r a n s m i s -
sion. Questionnaire data included initial stock levels for
each anti-malarial, date of opening the drug container/
box, date of emptying it/the stock level at revisit, and, if
drugs had been moved for other reasons than sale.
Dates were mostly based on shop registries, as reported
by shopkeepers. Counting of tablets, bottles or vials was
performed by the shopkeeper, observed by the inter-
viewer, after which monthly sale was calculated in units
of adult doses (except syrups, which were calculated as
child doses). Drug sale survey questionnaire data were
processed in Excel
®. To estimate the number of infants
accessing town, hospital immunization numbers was
used as a proxy, on the assumption that the choice of
immunization at a town hospital rather than at a village
dispensary was based on town access.
Ethics
Ethical clearance was granted by the Medical Research
Co-ordinating Committee of the Tanzania National
Institute for Medical Research, Tanzania. Shopkeepers
and owners volunteered as informants after written
informed consent, which guaranteed the confidentiality
of information, anonymity and freedom to withdraw
consent at any moment.
Results
Saleability
In-depth interviews with shopkeepers provided insight
into their experience with selling drugs; which kinds of
anti-malarials could be easily sold in Muheza and why?
Price
As expected, shopkeepers were aware that price was a
determining factor for the kinds of drugs they could
sell. The price of the cheapest ACT; a rare package of
ALu (Coartem
®) resold in a private shop, or more com-
monly a local brand of artesunate-sulfamethoxypyra-
zine-pyrimethamine, artesunate-SMP (Co-Arinate
®), was
four to seven times the cost of SP or SMP (Table 1).
Generally the variety of drugs offered in a shop reflected
its number of customers and likely added to its popular-
ity. The most popular shops offered several kinds of
ACT as alternatives to ALu, but with prices ranging up
to 10,000 Tsh (8 US$), the saleability was low. The retail
price of Coartem
® in the nearest licensed pharmacy (in
Tanga) was 12,000 Tsh. Shop owners explained, that for
as long as they were only allowed by the government to
buy ALu at the retail price, it was impossible for them
to sell it in Muheza. Only one shop offered ALu (Coar-
tem
®, two shops sold Co-Artesiane
®, ALu suspension,
b u ti r r e g u l a r l y ,a n dn o n eh a dt h e ma tt h et i m eo ft h e
drug sale interviews. However, most shopkeepers said
they had customers asking for ALu. If they came with a
prescription for ALu, shopkeepers reported they could
not change the prescription, but had to send them back.
Only if they asked for ALu without a prescription, could
customers be advised to buy e.g. metakelfin instead, as
one shop-owner explained: “they would agree then; peo-
ple know the process (of waiting) at the hospital“.H o w -
ever, customers liked that ALu was free, or they only
Table 1 Average anti-malarial drug prices in 16 private
shops in Muheza
￿ Amodiaquine: 500 Tsh*
￿ SP/SMP: 700 Tsh
￿ AQ/SP syrups: 1,000-1,500 Tsh
￿ Quinine injectable: 3 ampuls 1,800 Tsh
￿ Quinine syrup for infant < 5 kg: 2,000 Tsh
￿ (Rarely available) ALu (Coartem
®): 3,000 Tsh
￿ Artesunate-SMP (Co-Malafin
®): 3,500- 5,000 Tsh
￿ Artesunate-SMP (Co-Arinate
®) Junior: 7,500 Tsh
￿ ALu (Co-Artesiane
®) syrup: 8,000 Tsh
￿ Artemisinin-naphtoquine (ARCO
®): 8,000 Tsh
￿ Dihydroartemisinin-piperaquine (Duo-Cotexcin
®): 10,000 Tsh
*1000 Tsh = 0.8 US $
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hospital.
Preferences
According to shopkeepers, their customers preferred the
drugs they had become accustomed to after long time
use: “If they have used a drug since long time ago they
do not want to change, they remember the name“. “Each
person has their own preference (pendekezo)”,w a sa
common answer to why people bought the drugs they
bought, or, “these are his/her drugs“. Shopkeepers rarely
felt the need to advice against the preferences of the
customer. As one said, answering if he could sometimes
advise people to use AQ he thought was stronger and
better, instead of SP: “It is their right to say “no thanks!”
and say “then I prefer Fansidar
®“.
Shopkeepers said that their customers appreciated sin-
gle dose treatment for having side-effects for shorter
time, and many preferred Metakelfin
® (SMP) to other
SP, because it was only two pills instead of three, and
hence perceived stronger and better. However, import
of the brand Metakelfin
® had been banned recently fol-
lowing evidence that a fake product carrying its label
was widespread at the market. Local or imported Ken-
yan SMP was however still widely available, all referred
to as “metakelfin“ regardless of actual brand name.
Answering if they had had customers coming to the
shop after negative experiences with ALu, many shop-
keepers said they had heard some people in the commu-
nity saying they were getting fever again already the
same month after taking the drug, and when they went
t oac l i n i ct ob et e s t e dt h e yw e r es t i l lm a l a r i ap o s i t i v e .
Others stated they had received customers returning for
metakelfin after ALu treatment to finish the cure, or
who tried another drug than ALu for returning fever.
Side-effects
Evaluation of side-effects was said to be a major concern
for consumers, when they selected between kinds or
brands of anti-malarials. Shopkeepers said that their
customers were concerned that SP could cause allergy
(mzio), and dizziness (kizunguzungu) or headache
(kuumwa kichwa) perceived to arise from the “sulpha”
in SP. Such side-effects were said to vary with the qual-
ity of manufacturing, where Kenyan brands were often
valued above Tanzanian ones, and imported Metakelfin
®
had been very popular prior to the fake drugs scandal.
Shopkeepers themselves were aware that SP and “meta-
kelfin” were not alternative treatment options, but
reported that many customers bought them inter-
changeable or later shifted to a Kenyan brand, to find
out which they could tolerate best. Severe SP skin reac-
tions were termed babuka ngozi (disfiguring the skin),
explained as when a snake peels of its skin. One shop-
keeper said he had seen a similar ALu skin reaction on
TV. Customers, shopkeepers said, might also explain the
seriousness of side effects or discomfort to rise if the
diagnosis had been wrong (if they had taken anti-malar-
ials but had no malaria). The term for medicine (dawa)
is used also for poison, which might enhance popular
expectations of discomfort during treatment. Some cus-
tomers said that taking anti-malarials made them feel
exhausted: “T h ed r u gw e a k e n so n e( zinachosha), it is
strong (kali)”, and they feared to be unable to perform
normal duties during the treatment. The shorter the
duration, the better - hence the preference for SP. Some
people were trying out merely different brands of the
same drugs, to see which had least side-effects.
AQ was said often to cause nausea, dizziness and dis-
comfort and was felt to lower blood pressure (shusha
presha or moyo kuenda chini). Some customers never-
theless had AQ as “their drug"; shopkeepers explained
that they were the ones who felt they had reactions
from sulpha. Many shopkeepers explained the sensations
of low blood pressure as lowered sugar in the blood, and
said they advised their customers to take fruit or glucose
to prevent this.
QN, mostly taken as syrup or injectables, was said to
have worse side effects than AQ, including ‘ringing in
the ears’ (kelele masikioni), but could easier be accepted
as a strong yet necessary treatment, which people never-
theless were said to fear, because they knew it as the
final treatment (formerly third-line, now second-line).
Yet if they had got syrup for a child at the hospital an
earlier time, they might continue to want that when
their child got ill again, if they were satisfied with the
drug. Shopkeepers said they sold QN on prescription,
but differed in their opinion why health facilities were
prescribing but not dispensing the drug. Some answered
this was due to stock-outs at the hospital, others said
people took a shortcut by not waiting at the hospital
pharmacy before they could start treatment. When
asked if they knew of people’se x p e r i e n c e sw i t hA L u ,
although they were not themselves offering it for sale,
shopkeepers told that ALu was a drug that did not have
major side effects and people appreciated that.
Sale
All 20 (100%) shops sold SP or sulphamethoxypyrazine-
pyrimethamine (SMP), AQ and QN in oral children and
adult formulations, QN also as injectable. CQ was sold
in one shop, said to be for the malaria chemoprophy-
laxis for sickle cell disease patients (in accordance with
national guidelines). Only half of the shops sold ACT,
and none sold artemisinin mono-therapy. The calculated
monthly sale of anti-malarials in the16 shops participat-
ing in the December drug sales survey was 4,041 doses,
which if extrapolated to a full year, indicates that at any
given month a quarter of the town population are self-
medicating febrile illness with an anti-malarial bought
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eral population regardless of age was by far dominated
by SP sale; brands of SP accounted for 74% of sales
volume, equally divided between brands of SP and SMP
(36% and 38% respectively). AQ accounted for 13%, and
QN 11%, mainly as syrup or injectable. ACT accounted
for only 2% of sale, mainly as Co-malafin
® (artesunate-
SMP) or Duo-cotexcin
® (dihydroartemisinin -pipera-
quine). SP and AQ together (3,503 doses) would amount
to the consumption of 2.8 doses of non-recommended
anti-malarials per person per year.
At least 15% (619 doses) of drugs sale was to young
children, based on the proportion of syrups of the total
sale (Figure 1). Shops were providing 209 doses of qui-
nine syrup monthly, sold in bottles containing only an
adequate dose for an infant up to five kg, which is in
accordance with guidelines when sold as first-line treat-
ment. However, the insert drug information provides
dosage regimes for children up to six years, without spe-
cifying that this is beyond the content, and infants are
not weighed in drug shops. An estimated 1,412 infants
in Muheza have access to shops in town; the number
also brought to the town district hospital for immuniza-
tion, rather than to village dispensaries (immunization
coverage is high; 84% for diphtheria-tetanus-polio 3
(DTP) in Tanzania) [18]. The sale of quinine syrup from
shops can be extrapolated to 2,508 infant doses
annually; an estimated 1.8 dose pr. infant per year. This
likely indicates, that at least one dose is taken when the
infant is above five kilo, and the bottle will not last for a
full one-week treatment.
On top of the problem of a recommended drug (QN)
sold at a non-recommended age, no less than 410 anti-
malarial syrups were sold per month; 66% of syrup sale
(Figure 2), was not quinine, but non-recommended anti-
malarial, mainly AQ.
Discussion
High saleability of non-recommended anti-malarials
The continued private market for SP even after policy
change is an interesting phenomenon, potentially with
important lessons to be learned for the present and
future anti-malarial drug policy changes. In the public
sector, patients are not confronted with the choice of
having to make evaluations of drug efficacy or “value for
money”. But the private sector offers that opportunity,
and hence the demand for decision making, which is
most often left to the customer, based on his/her knowl-
edge and understanding of symptoms, ability and will-
ingness to pay, and experiences and preferences of
drugs. Evidently this leads to the purchase of cheap
anti-malarials, even if no longer recommended in policy.
Locally, malaria is considered a form of homa (fever),
and lay evaluations of drug efficacy is informed by cul-
tural knowledge of illness [17]. If shopkeepers are right
about their customers’ views upon the drugs they sell -
and the continued sale seems to support this - then peo-
ple in Muheza still consider the cheapest drugs at the
private market; AQ and SP (including SMP), to be effi-
cacious drugs, that will keep them free from homa for
long. According to shopkeepers, the vast majority of
customers buying SP or metakelfin did so, because they
found the drug was still working. The presence of this
trust is supported by the magnitude of sale of these
drugs - there is evidently still a market for anti-malarial
mono-therapies in Muheza.
Although it can be argued that the alleged continued
trust in the value of SP and AQ is informed by necessity
- these are the sole drugs that are affordable to people -
the alternative remains for them to obtain drugs from
public facilities. As town dwellers with the option to
chose between public and private sources of treatment,
a substantial proportion of caretakers or patients in
Figure 1 Percentage of anti-malarial doses sold as syrup in 16
private drugshops in Muheza, Dec. 2009, Total 619 doses.
Figure 2 Distribution of anti-malarial syrup sales volume in 16
private drugshops in Muheza, Dec. 2009, Total 619 doses.
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below, in spite of the fact that here, ACT was 50% una-
vailable and 100% unsubsidized.
The scale of private sale
Considering the size of the town; 15,000 residents, the
study found a very high utilization of drug shops for the
purchase of other anti-malarials, SP and SMP in particu-
lar, although these were officially replaced by ACT three
years earlier. The large volume of anti-malarials sold in
Muheza is surprising, considering that customers may
often buy antipyretics without an anti-malarial as their
first choice, and self-diagnos em a l a r i ao n l ya f t e ra n t i -
pyretic failure to lower fever [19]. However, observations
of customers initially asking solely for antipyretics were
rare - while these drugs were widely available in small
general kiosks.
The private sector’s share of the total dispensing of
anti-malarials in the community is high, when compared
with secondary data from the district hospital out-
patient-department. The OPD at the District hospital
Teule, the main source of primary health care for people
in Muheza town, sees 31,075 new outpatients annually,
among these 3,680 are children treated for malaria and/
or anaemia [20]. Private drug shops provided an extra-
polated 7,428 doses of anti-malarial syrup annually, i.e.
more than double the OPD child malaria treatments at
the hospital. Using the sale of anti-malarial syrups as a
proxy for the proportion of anti-malarials sold to chil-
dren is likely an underestimation; the price for syrup
was double the price of tablets, and even if these could
only be bought in pre-packaged adult doses they were a
cheaper alternative. When at least two of every three
child malaria treatments to non-hospitalised children
are with drugs obtained from private shops, and two
third of them are with non-recommended anti-malarials,
it can be estimated that, unless admitted to hospital,
almost half (44%) of Muhezan children treated for clini-
cal malaria are not treated in accordance with national
guidelines.
For the general population as for the children, care
seeking outside the formal sector was frequent in private
drug shops; the amount of anti-malarial drugs dispensed
here accounted for an estimated three quarters of clini-
cal malaria treatments in the community, as based on
comparison with data [20] from the district hospital.
Community SP drug pressure and resistance
Extrapolated to a year, private shops were providing
each town inhabitant with almost three non-recom-
mended anti-malarial doses per year; by far the major-
ity of which would be with SP. This equals “de facto
intermittent presumptive treatment”,o t h e r w i s e
reserved for pregnant women. IPTp with SP is the only
recommended treatment option to prevent maternal
anaemia, placental malaria and adverse birth outcomes,
as long as the safety of ACT for IPT during pregnancy
remains unascertained.
High level of drug pressure in a community can
rapidly lead to community-wide drug resistance, as has
been shown for SP in Muheza already in 1994 [16]. A
reduction in community drug resistance can be effected
by known means, such as reducing the drug pressure by
expanding the coverage of insecticide treated net owner-
ship to the general population, not just to pregnant
women and children [21,22], and, by ensuring the com-
munity’s access and use of ALu, which is effective also
in suppressing transmission [23].
SP drug resistance remains a reason for concern, for
as long as SP is the only available recommended drug
option for IPTp. The drug resistance data most recently
published from Muheza come from clinical trials of
IPTp, showing that IPTp use offered only partial protec-
tion and left those unprotected to suffer from a more
intense infection, with increasing parasitaemia and a sig-
nificantly higher fraction of highly resistant parasites as
compared to infections in non-users of IPTp. The mean
fraction of resistant parasites was 0.31 and increased by
0.15 each year from 2002 to 2005 [24]. A similar trend
was found in nearby Korogwe, from ordinary treatment
while SP was first-line drug. Here, a four-fold increase
in the fraction of triple mutant resistance type parasites
in infections was observed, from 8% in 2003 to 32% in
2007, along with a fivefold decline in parasite prevalence
from 79% in 2003 to 15.5% in 2007 [25], indicating that
the parasite pool for the transmission of drug resistant
infection has remained relatively unaffected in size, in
spite of the overall transmission decline.
Most recent data from the area (D. Ishengoma, perso-
nal communication) indicate that while presence of
molecular markers reflecting CQ resistance may be
declining, molecular markers for SP resistance remain
high.
The present study adds to these findings, by demon-
strating that the drug pressure in the community caused
by the availability of SP in private drug shops even after
an a t i o n a ld r u gp o l i c yc h a n g e ,e q u a l sde facto intermit-
tent presumptive treatment not only by pregnant
women, but by the community at large.
Identified need for intervention
It is heartening that artemisinin mono-therapy, observed
by the P.I. to be for sale in Muhezan drug shops in
2004 was no longer sold in any shops, indicating that a
national ban since 2008 had been effective. However,
prescription-only SP sales e.g. illicit sale remained high:
74% of total anti-malarial sale in private drug shops in
Muheza. These data support the findings of a 2008-9
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accounted for three quarters of the sale of anti-malarials
in private drug shops [26]. Even in Morogoro region,
where the ADDO programme is already implemented,
65% of anti-malarial customers received SP, and only
13% received ALu [27]. The present study has shown
that, although ACT is available in private shops, it is
only accessed by a minority of the population. Increased
access is blocked by lack of affordable recommended
drugs at the private market, leaving the customers with
older remedies, which they trust in and can afford and
easily access from the private sector.
The persistence of a market for non-recommended
drugs for self-medication risks undermining a public
good; the efficacy of IPT for pregnant women. Policy
and programme management of private distribution of
anti-malarials are concerned with promoting shops’
access to quality drugs to dispense.T h e ym u s te q u a l l y
confront the problem how a parallel market for non-
recommended drugs is effectively dispensed with. Train-
ing and accreditation of private drug dispensers is highly
recommended, but should be followed up by studies on
actual practice and performance.
Study limitations
The observational study required the confidence of drug
sellers working in an informal business sphere, where
specialist drug stores unlicensed to sell prescription-only
drugs nevertheless did so. This may have limited the
sharing of confidential information. The question of the
proportion of drug sale that was actually on prescription
was left undiscovered for this reason. Sale without pre-
scription could however be freely observed in all drug
shops for the most commonly sold drugs.
With a singular focus on the private sector, the study
only presents secondary data on the prescription prac-
tice in the public sector in Muheza, e.g. hospital statis-
tics from the designated district hospital Teule, and only
on diagnoses, not on treatments given [20]. As town
inhabitants are free to seek care at the hospital OPD
without prior referral, utilization of the public dispen-
sary in Muheza town tends to be marginal, wherefore
data missing from this facility would hardly have any
impact.
The likely overlap in clients of the two kinds of facil-
ities, hospital OPD patients and drug shop customers
has not been established. Adjusting for any overlap
would increase the relative proportion treated by private
drug shops. Finally, it can only be assumed that pur-
chased drugs are in fact consumed.
Conclusions
An estimated three of every four cases of suspected
malaria among the general population in Muheza were
treated in the private sector, and almost nine of ten
customers here obtained SP or AQ. Hence two of
every three cases, considered as clinical malaria cases
in the community, failed to get treated in accordance
with national guidelines. The national malaria treat-
ment policy reserves SP strictly for IPTp, and yet the
drug is consumed almost thrice a year by the general
population.
Considering the already very high level of drug resis-
tance in the area, and the likelihood that a continuation
of SP drug pressure will only aggravate the problem
further, it is a major reason for concern that shops pro-
vide de facto intermittent presumptive treatment to the
majority of the community. This is inappropriate treat-
ment not only for the customers; it may compromise
the strategy of IPT for pregnant women and render the
safe SP use during pregnancy ineffective.
This might, in the end, redu c et r u s ti na n di m p a c to f
the entire national malaria control. Training and accred-
itation - and supervision - of private drug dispensers is
highly recommended.
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